Under the agreement, Bio-Thera will maintain responsibility for the development, manufacturing, and supply of BAT2206 and BAT2506

Bio-Thera Solutions a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and Dr Reddy’s Laboratories have reached commercialisation and license agreements for BAT2206, a Proposed Stelara Biosimilar and BAT2506, a proposed Simponi Biosimilar.

Under the agreement, Bio-Thera will maintain responsibility for the development, manufacturing, and supply of BAT2206 and BAT2506. Dr Reddy’s will be responsible for seeking regulatory approvals as
well as commercialisation in the licensed territories in Southeast Asia, including

In addition, Dr Reddy’s will also receive the exclusive commercial rights to BAT2206 in Colombia.

“This is our first partnership focused solely on Southeast Asia and Dr Reddy’s is the perfect partner to help bring BAT2206 and BAT2506 to patients in the region”, said Dr Shengfeng Li, CEO of Bio-Thera. “Bio-Thera believes in the health and welfare of patients around the world and this
collaboration with Dr Reddy’s demonstrates our commitment to the patients in Southeast Asia.”

MV Ramana, CEO – Branded Markets (India & Emerging Markets), Dr Reddy’s, said, “Our partnership with Bio-Thera enables us to further expand our biosimilars offerings in the emerging markets. With our well-established commercial strengths in these markets, we look forward to addressing the unmet needs of patients with access to affordable medicines.”